In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers's Grand Ambitions in Oncology

Executive Summary

Bristol-Myers aims to become an oncology powerhouse in the next five years. Through M&A, alliances, and internal R&D, Bristol-Myers is building an armamentarium of oncology assets that allows it to take multiple "shots on goal." It is leveraging its past experiences in the field as it also adds new skill sets in biologics, market access, and biomarkers. But the market has become more competitive, as companies look to participate in one of the few growth areas of pharma. Bristol, like others, is carving out space in the Avastin-ineligible or -intolerant portion of the market, particularly in the gastrointestinal, colorectal, and head-and-neck cancer areas. Even if successful, current late-stage development projects aren't likely to contribute much to revenues before 2011-and oncology products have slow ramp-ups. With a patent cliff looming in 2012, the company needs new products now.
Advertisement

Related Content

Making The Case For Antibody-Drug Conjugates
Can BMS Deliver on Innovation?
Bristol-Myers Squibb and Otsuka Stabilize Their Bases
End of an Era for GSK and Exelixis
Pfizer's Increasingly Specialist Focus
Pfizer's Increasingly Specialist Focus
Eli Lilly's Oncology Focus
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Bristol's Billion-Dollar Ante to Stay in the Cancer Game
Bristol's Billion-Dollar Ante to Stay in the Cancer Game

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel